Improving patient care: expert nursing and service development.

about

Improving patient care: expert nursing and service development.

Item

http://www.wikidata.org/entity/Q49581531

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Improving patient care: expert nursing and service development.

@en

Improving patient care: expert nursing and service development.

@nl

type

Item

label

Improving patient care: expert nursing and service development.

@en

Improving patient care: expert nursing and service development.

@nl

prefLabel

Improving patient care: expert nursing and service development.

@en

Improving patient care: expert nursing and service development.

@nl

P1476

Improving patient care: expert nursing and service development.

@en

P2093

Claire Ryan

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

Benefits of multidisciplinary teamwork in the management of breast cancer

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

P304

S21-S25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12968/BJON.2017.26.SUP16A.S21

http://www.w3.org/2001/XMLSchema#string

P433

Sup16a

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28981329

http://www.w3.org/2001/XMLSchema#string